This finding further supports the potential clinical utility of PDK1 as a biomarker for osteosarcoma.Although our study focused on the effects of PDK1 silencing in osteosarcoma, multiple studies have shown that PDK1 overexpression enhances tumor aggressiveness. The gene discussed is PDK1; the disease is neoplasm.